Millions can start opioid treatment from home as telehealth buprenorphine rule becomes permanent
A federal rule issued this month permanently allows prescribing of buprenorphine for opioid use disorder via telemedicine, a change officials say will let millions of Americans begin lifesaving treatment without an in-person clinic visit. The Drug Enforcement Administration and Department of Health and Human Services finalized regulations in mid January 2025 that codify flexibilities first put in place during the COVID public health emergency. The move removes a key barrier for patients who lack transportation, live in rural areas, or face stigma when seeking care.
What the rule does
Under the new DEA rule, a clinician may initiate buprenorphine treatment through a telemedicine encounter, including a telephone consultation in specific circumstances, and may provide an initial supply as long as required safeguards are met. The rule explicitly allows a patient to receive a six month supply of buprenorphine after a telemedicine encounter in certain situations, while subsequent longer term prescribing may require further evaluation. The regulations also establish registration requirements for online platforms that connect patients with prescribers and call for steps toward a nationwide prescription drug monitoring system.
Why it matters now
Federal survey data show that roughly 6.1 million people met criteria for opioid use disorder in recent national estimates. Fewer than 1.2 million of them received medication for opioid use disorder in the past year, leaving a large treatment gap where telehealth could have outsized impact. Experts and advocates have long argued that easier remote access to buprenorphine can reduce delays to treatment and cut overdose risk. The agencies framed the rule as a public health intervention intended to expand access while building safeguards to limit diversion.
Overdose context
The change comes amid persistently high overdose mortality. Provisional data from the Centers for Disease Control and Prevention show there were an estimated 107,543 drug overdose deaths in 2023, driven largely by synthetic opioids. Reducing barriers to medication treatment is a cornerstone of federal overdose prevention strategies.
Implementation and next steps
The DEA rule accompanies related actions by HHS and SAMHSA to align clinical guidance and to weave telehealth options into existing treatment programs. Regulators also proposed a special registration pathway that could allow some clinicians to prescribe controlled medications by telemedicine without any prior in-person visit, subject to additional requirements. States, health systems, and clinicians will need to update policies, workflows, and privacy practices to operationalize the change.
Bottom line
For people with opioid use disorder, the new rule removes a common practical barrier to starting medication treatment. Policymakers framed the change as both a widening of access and a tightening of oversight. The extent to which telehealth expansion translates into more people sustained on evidence based treatment will depend on clinician adoption, insurance coverage, and continued monitoring for safety and diversion.